The Role of the Pharmacist in Identifying Signs of Opioid Use Disorder

This activity is part of a series

Faculty

John G. Gums, PharmD, FCCP
Associate Dean for Clinical and Administrative Affairs, Professor of Pharmacy and Medicine, College of Pharmacy, University of Florida, Gainesville, FL
John G. Gums, PharmD, FCCP

Dr. Gums is a Professor of Pharmacy and Medicine in the Departments of Pharmacotherapy and Translational Research and Community Health and Family Medicine at the University of Florida. Additionally, he holds the title of Associate Dean for Clinical and Administrative Affairs in the College of Pharmacy. He received his undergraduate degree in pharmacy from the University of Wisconsin and his Doctor of Pharmacy degree from the Medical University of South Carolina. Subsequently, he completed a post-doctoral fellowship in Family Medicine at the Medical University of South Carolina. Dr. Gums is actively involved in teaching both in the College of Pharmacy and the College of Medicine. He has received the Faculty Recognition Award from the College of Pharmacy, Exemplary Teacher Award from the College of Medicine, and twice was selected as Teacher of the Year by the University of Florida, Department of Family Medicine.

He has authored over 200 peered-review articles, 26 continuing education programs, and 24 book chapters. He has given over 110 invited presentations to national and international pharmacy and medical associations. He maintains an active clinical research program, including past funding from the NIH. Currently, he is a co- investigator on numerous NIH-funded trials evaluating the impact and role of pharmacogenomics in the treatment of patients with hypertension.

Dr. Gums maintains membership in ASHP, AACP, and ACCP. He is a member of the Family Medicine Editorial Advisory Council for the Annals of Pharmacotherapy, and is a Scientific Editor for the journal Pharmacotherapy. In 1993, he was appointed by the governor as a member of the State of Florida Pharmacy Services and Technical Review panel. In 1997, he received the Outstanding Clinical Practice Award from ACCP. In 2002, Dr. Gums served as a Primary Health Care Policy Fellow through the office of the Secretary of Health and Human Services in Washington DC. And in 2007, he was elected as a Fellow in the American College of Clinical Pharmacy.

Carol Anne A. Motycka, PharmD, BCACP
Assistant Dean for Jacksonville Campus, Campus Director & Clinical Associate Professor, University of Florida College of Pharmacy, Jacksonville Campus, Jacksonville, FL
Carol Anne A. Motycka, PharmD, BCACP

Dr. Carol Motycka graduated from the University of Florida with her Pharm.D. and completed a residency in Ambulatory Care at Florida Hospital in Orlando. After practicing at Florida Hospital for several years, Dr. Motycka joined the University of Florida to help build the College of Pharmacy program in Jacksonville. She is board certified in Ambulatory Care and has completed fellowships in both leadership and education. Dr. Motycka has been published in multiple academic and clinical journals and has provided over 100 presentations in the field with a particular focus on substance use disorders utilizing interprofessional education, simulation, and teamwork. She has received awards on the state and National level for her teaching, research, and leadership. As Assistant Dean of the University of Florida College of Pharmacy Jacksonville Campus, Dr. Carol Motycka spends her time teaching, completing research, advising, and administrating.

Statement of Need

The impact of opioid on the United States and its communities is a constantly growing burden and is challenging for patients and the health care community. Pharmacists are important members of the treatment team, particularly when it comes to addressing the opioid crisis. Awareness, patient communication, and education as well as bidirectional communication with prescribers are all imperative to doing what is best for the patient. This includes identifying and using appropriate screening tools and reviewing available options for naloxone and medicated assisted treatment (MAT) for individuals with opioid use disorder.

This CMEOCast podcast episode features expert faculty focused on the role of the pharmacist in communicating with patients about their prescribed opioids and in recommending and/or dispensing naloxone to individuals prescribed opioids who may be at risk for overdose, and available options for medicated assisted treatment (MAT).

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Identify screening tools for opioid use disorder that can be used by pharmacists.
  • Examine the role of the pharmacist in recommending and/or dispensing naloxone to individuals prescribed opioids who may be at risk for overdose.
  • Review available options for medicated assisted treatment (MAT) for individuals with opioid use disorder.

Financial Support

Supported by an educational grant from Johnson & Johnson.

Target Audience

Pharmacists

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacists (ACPE) 0.5

This application-based activity is approved for 0.5 contact hours (0.05 CEUs) of continuing pharmacy credit.
Activity UAN: JA0007185-0000-22-038-H08-P

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.

John G. Gums, PharmD, FCCP, has no disclosures to report.

Carol Anne A. Motycka, PharmD, BCACP, has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:

  • Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Obtaining Credits

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at (877) CME-PROS or (877) 263-7767.

PD-010-090919-00

 

 

The Role of the Pharmacist in Identifying Signs of Opioid Use Disorder
Event Date: 09/09/2019